[ejstronge]

This is an area I work in professionally so I keep up with the technical side of things.

> once you start adding more than one item to a cell it doesn't always work out.

Very true, but the amounts of money at stake would justify the relatively inexpensive cost of hooking cells up to the already-available ER/TR-responsive gene elements.

> but I don't believe any before have contained these immune escaping edits

Hard to say, I'm not an expert on immune escape. It's an old idea, however, so I imagine it's been used in other pre-clinical or Phase 1 settings.

> I believe all of those treatments are cancer treatments which allow for a different level of risk

I imagine you're speaking about allogeneic treatment? Either way, this isn't true at all - here's a list of current treatments for diabetes alone:

https://pmc.ncbi.nlm.nih.gov/articles/PMC12401705/#s4

[DarwinsToffees]

I also work in this field and while I largely agree with you, cell therapy is one of the hardest hit fields right now financially and investing in big shots to do something like dual edited islet cells is probably not going to happen. Maybe in the distant future, but right now I don't see someone going for that seriously in a clinical setting.